Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board. [FR Doc. 2023–03124 Filed 2–13–23; 8:45 am] BILLING CODE P

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090–XXXX; Docket No. 2023–0001; Sequence No. 1]

Information Collection; Overseas Employment Agreement; GSA Form 5040

AGENCY: Office of Human Resource Management, Division of Human Capital Policy and Programs, General Services Administration (GSA). **ACTION:** Notice of request for comments regarding a request for a new OMB clearance.

SUMMARY: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division will be submitting to the Office of Management and Budget (OMB) a request to review and approve a new information collection requirement.

DATES: Submit comments on or before April 17, 2023.

ADDRESSES: Submit comments identified by Information Collection 3090–XXXX; Overseas Employment Agreement; GSA Form 5040 to: http:// www.regulations.gov.

Submit comments via the Federal eRulemaking portal by searching for "Information Collection 3090-XXXX; **Overseas Employment Agreement; GSA** Form 5040". Select the link "Submit a Comment" that corresponds with "Information Collection 3090-XXXX; **Overseas Employment Agreement; GSA** Form 5040". Follow the instructions provided at the "Submit a Comment" screen. Please include your name, company name (if any), and "Information Collection 3090-XXXX; **Overseas Employment Agreement; GSA** Form 5040" on your attached document. If your comment cannot be submitted using https://www.regulations.gov, call or email the points of contact in the FOR FURTHER INFORMATION CONTACT section of this document for alternate instructions.

Instructions: Please submit comments only and cite Information Collection 3090–XXXX; Overseas Employment Agreement; GSA Form 5040, in all correspondence related to this collection. Comments received generally will be posted without change to http:// www.regulations.gov, including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check *www.regulations.gov*, approximately two-to-three days after submission to verify posting.

FOR FURTHER INFORMATION CONTACT:

Colin C. Bennett, Human Resources Specialist, Office of Human Resources Management, Division of Human Capital Policy and Programs, at telephone 240–418–6822 or via email to *colin.bennett@gsa.gov* for clarification of content.

SUPPLEMENTARY INFORMATION:

A. Purpose

The General Services Administration routinely hires, reassigns, promotes or transfers Federal employees to duty stations in foreign areas (*i.e.*, outside of the United States and its territories and possessions). Under the Administrative Expenses Act of 1946 (60 Stat. 808), as amended, agencies are permitted to use appropriated funds to pay for the various costs incurred for permanent change of station (PCS) to the foreign area (see further 5 U.S.C. 5722 et. seq.). Such costs include: (1) travel expenses of the new appointee (or employee) and transportation expenses of his or her immediate family and his household goods and personal effects from the place of actual residence at the time of appointment to the place of employment outside the continental United States; (2) these expenses on the return of an employee from his post of duty outside the continental United States to the place of his actual residence at the time of assignment to duty outside the continental United States; and (3) the expenses of transporting a privately owned motor vehicle as authorized under 5 U.S.C. 5727(c). Under this authority, in return for this travel and transportation benefit, the appointee (or employee) must remain in the agency's service for 12 months (1 year). More information concerning this statutory requirement is found within the GSA Government Travel Regulations at 41 CFR part 302-3, subpart F.

In order to more effectively memorialize the agency costs incurred, and the appointee's (or employee's) resulting service obligation, GSA has redeveloped its existing form GSA 5040. The intent is for this form to be used: (1) as an information collection device to memorialize compensation, foreign allowance, and travel and transportation benefits provided, and (2) as an enforceable service agreement for PCS travel and transportation costs, pursuant to the Federal Claims Collection Act of 1966 and the Debt Collection Act Amendments of 1996 (see further 31 U.S.C. 3711 et. seq.)

B. Annual Reporting Burden

Respondents: 25 per year. Responses per Respondent: 1. Total Annual Responses: 25. Hours per Response: 1. Total Burden Hours: 25.

C. Public Comments

Public comments are particularly invited on: Whether this collection of information is necessary, whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate, and based on valid assumptions and methodology; ways to enhance the quality, utility, and clarity of the information to be collected; and ways in which we can minimize the burden of the collection of information on those who are to respond, through the use of appropriate technological collection techniques or other forms of information technology.

Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the Regulatory Secretariat Division by calling 202–501–4755 or emailing *GSARegSec@gsa.gov.* Please cite OMB Control No. 3090–XXXX, Overseas Employment Agreement; GSA Form 5040, in all correspondence.

Beth Anne Killoran,

Deputy Chief Information Officer. [FR Doc. 2023–03131 Filed 2–13–23; 8:45 am] BILLING CODE 6820–FM–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2013-N-0134; FDA-2016-D-2565; FDA-2013-N-0514; FDA-2015-N-0030; FDA-2021-N-0584; FDA-2021-N-1026; FDA-2013-N-0557; FDA-2014-N-0053; FDA-2013-N-0190; FDA-2019-N-0305; FDA-2019-N-2854; FDA-2019-N-5553; FDA-2017-D-0085; FDA-2016-N-2544; FDA-2019-N-2778; FDA-2012-N-0977; FDA-2010-D-0319; and FDA-2018-N-3728]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. **FOR FURTHER INFORMATION CONTACT:** JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796– 3794, *PRAStaff@fda.hhs.gov.* **SUPPLEMENTARY INFORMATION:** The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting

statements for the information collections are available on the internet at *https://www.reginfo.gov/public/do/ PRAMain.* An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB

Title of collection	OMB control No.	Date approval expires
Mammography Standards Quality Act Requirements	0910-0309	11/30/2025
510(k) Third-Party Review Program	0910-0375	11/30/2025
Administrative Procedures for Clinical Laboratory Improvement Amendments of 1988 Categorization	0910-0607	11/30/2025
Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act	0910-0800	11/30/2025
Pilot to Develop Standardized Reporting Forms for Federally Funded Public Health Projects and Agreements	0910-0909	11/30/2025
Text Analysis of Proprietary Drug Name Interpretations	0910-0910	11/30/2025
Postmarket Surveillance of Medical Devices	0910-0449	12/31/2025
Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods	0910-0560	12/31/2025
Warning Plans for Smokeless Tobacco Products	0910-0671	12/31/2025
Deeming Tobacco Products To Be Subject to the FD&C Act	0910-0768	12/31/2025
Premarket Tobacco Product Applications and Recordkeeping Requirements	0910-0879	12/31/2025
Right to Try Act: Reporting Requirements	0910-0893	12/31/2025
Substances Generally Recognized as Safe: Best Practices for Convening a GRAS Panel	0910-0911	12/31/2025
Medical Devices—Quality System Regulation; 21 CFR part 820	0910-0073	1/31/2026
Threshold of Regulation for Substances Used in Food-Contact Articles	0910-0298	1/31/2026
Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children		
and Adolescents	0910-0312	1/31/2026
Mailing of Important Information About Drugs	0910-0754	1/31/2026
Collection of Conflict of Interest Information for Participation in Food and Drug Administration Non-Employee		
Fellowship and Traineeship Programs	0910-0882	1/31/2026

Dated: February 8, 2023.

Lauren K. Roth,

Associate Commissioner for Policy. [FR Doc. 2023–03073 Filed 2–13–23; 8:45 am] BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2018-E-3051 and FDA-2018-E-3095]

Determination of Regulatory Review Period for Purposes of Patent Extension; ALIQOPA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALIQOPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

DATES: Anyone with knowledge that any of the dates as published (see the **SUPPLEMENTARY INFORMATION** section) are incorrect may submit either electronic or written comments and ask for a redetermination by April 17, 2023. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 14, 2023. See "Petitions" in the **SUPPLEMENTARY INFORMATION** section for more information.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The *https:// www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of April 17, 2023. Comments received by mail/hand delivery/courier (for written/ paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal:

https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

• Mail/Hand Delivery/Courier (for written/paper submissions): Dockets